Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Thomas Meyer to Lung Neoplasms

This is a "connection" page, showing publications Thomas Meyer has written about Lung Neoplasms.

 
Connection Strength
 
 
 
0.297
 
  1. Furusawa T, Cavero R, Liu Y, Li H, Xu X, Andresson T, Reinhold W, White O, Boufraqech M, Meyer TJ, Hartmann O, Diefenbacher ME, Pommier Y, Weyemi U. Metabolism-focused CRISPR screen unveils mitochondrial pyruvate carrier 1 as a critical driver for PARP inhibitor resistance in lung cancer. Mol Carcinog. 2024 Jun; 63(6):1024-1037.
    View in: PubMed
    Score: 0.086
  2. Dabrow MB, Francesco MR, Gilman PB, Cantor R, Rose L, Meyer TJ. Combined therapy with topotecan and gemcitabine in patients with inoperable or metastatic non-small cell lung cancer. Cancer Invest. 2003; 21(4):517-25.
    View in: PubMed
    Score: 0.079
  3. Berent TE, Dorschner JM, Meyer T, Craig TA, Wang X, Kunz H, Jatoi A, Lanza IR, Chen H, Kumar R. Impaired cardiac performance, protein synthesis, and mitochondrial function in tumor-bearing mice. PLoS One. 2019; 14(12):e0226440.
    View in: PubMed
    Score: 0.064
  4. Shen X, Denittis A, Werner-Wasik M, Axelrod R, Gilman P, Meyer T, Treat J, Curran WJ, Machtay M. Phase i study of 'dose-dense' pemetrexed plus carboplatin/radiotherapy for locally advanced non-small cell lung carcinoma. Radiat Oncol. 2011 Feb 16; 6:17.
    View in: PubMed
    Score: 0.035
  5. Chang MY, Boulden J, Katz JB, Wang L, Meyer TJ, Soler AP, Muller AJ, Prendergast GC. Bin1 ablation increases susceptibility to cancer during aging, particularly lung cancer. Cancer Res. 2007 Aug 15; 67(16):7605-12.
    View in: PubMed
    Score: 0.027
  6. Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 2004 Jul 15; 64(14):4931-41.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)